Kaplan–Meier survival analysis of breast cancer patients (n = 148) demonstrated co-expression of GFAT and HAS2 to be more significantly associated with worse overall patient survival than the respective expression of GFAT or HAS2 alone (Fig. 1b). This evidence concerns the gene HAS2 and breast carcinoma.